Biosimilar pegfilgrastim regulatory update

FDA accepted for review a BLA from Coherus for CHS-1701, a biosimilar of neutropenia drug Neulasta pegfilgrastim. Its action date under the Biosimilar User Fee Act (BsUFA) is June 9, 2017. Amgen Inc...